EPTIFIBATIDE INJECTION 2 MG
EPTIFIBATIDE : 2 MG · DIN 02422859 · STRIDES PHARMA CANADA INC
Health Canada status: APPROVED
What is EPTIFIBATIDE INJECTION?
EPTIFIBATIDE INJECTION 2 MG contains EPTIFIBATIDE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02422859, held by STRIDES PHARMA CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 26-Aug-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02422859 |
|---|---|
| Brand name | EPTIFIBATIDE INJECTION |
| Generic / active ingredient | EPTIFIBATIDE : 2 MG |
| Manufacturer | STRIDES PHARMA CANADA INC |
| Strength | 2 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | B01AC16 EPTIFIBATIDE |
| AHFS class | 20:12.18 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 26-Aug-2020 |
What can be used instead?
Other Canadian products sharing ATC code B01AC16 EPTIFIBATIDE. 2 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| EPTIFIBATIDE INJECTION | 0.75 MG | Solution | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02540819 |
| EPTIFIBATIDE INJECTION | 2 MG | SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02540827 |
| EPTIFIBATIDE INJECTION | 0.75 MG | SOLUTION | OMEGA LABORATORIES LIMITED | CANCELLED PRE MARKET | DIN 02410109 |
| EPTIFIBATIDE INJECTION | 0.75 MG | SOLUTION | STRIDES PHARMA CANADA INC | APPROVED | DIN 02422840 |
| EPTIFIBATIDE INJECTION | 0.75 MG | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02405083 |
| EPTIFIBATIDE INJECTION | 0.75 MG | SOLUTION | ACCORD HEALTHCARE INC | CANCELLED PRE MARKET | DIN 02454483 |
| EPTIFIBATIDE INJECTION | 0.75 MG | SOLUTION | FRESENIUS KABI CANADA LTD | CANCELLED PRE MARKET | DIN 02460378 |
| EPTIFIBATIDE INJECTION | 2 MG | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02367858 |
| EPTIFIBATIDE INJECTION | 2 MG | SOLUTION | ACCORD HEALTHCARE INC | CANCELLED PRE MARKET | DIN 02454491 |
| EPTIFIBATIDE INJECTION | 2 MG | SOLUTION | FRESENIUS KABI CANADA LTD | CANCELLED PRE MARKET | DIN 02460386 |
Who else supplies EPTIFIBATIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. EPTIFIBATIDE appears in 7 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.